About Spectrum Oncology Private Limited
Data last updated:
Spectrum Oncology Private Limited is a private limited company based in Mumbai, Maharashtra, India, a subsidiary of Spectrum Pharmaceuticals Inc Usa. The company is currently under liquidation, meaning its assets are being sold to settle outstanding debts. It may not have the legal capacity to fulfil new contracts. It operates in the pharma contract r and d segment of the pharmaceuticals sector. It was incorporated on 01 May 2008.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U51397MH2008PTC181835. Its GSTIN is 27AABCO0640G1ZT (Maharashtra).
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹1.9 Lakh. It was formerly known as Oncorx Pharma Private Limited. It is led by directors including Arun Shankar Nanivadekar and Hemanshu Lalitbhai Kapadia (Irp/Rp/Liquidator).
Its last annual general meeting (AGM) was held on 05 July 2023, and its latest financial statements are for the year ended 31 March 2023. The registered office is at Mumbai, Maharashtra.
As per the financials filed for FY 2023, the company reported a revenue of ₹3.91 Cr, a growth of 14% compared to the previous year. For the same year it recorded a net profit of ₹29.95 Lakh (net margin 7.7%) and EBITDA of ₹45.32 Lakh (EBITDA margin 11.6%). Revenue has grown at a compounded annual rate (CAGR) of 6% over three years and 1% over five years.
The company is associated with 1 brand: Spectrum Pharmaceuticals.
The last known website on record is sppirx.com.
Company details
Contact details
Spectrum Oncology Private Limited's registered office is in Mumbai, Maharashtra. Its website is sppirx.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressOfc No 1 Sadhana Bldg Gr Flr 207, David Barreto Rd Opp Wadala Stn Wadala West, Mumbai, Maharashtra, India – 400031
- IndustryPharma, Pharma Contract R&D
To see the full contact details of Spectrum Oncology Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Spectrum Oncology operates one associated brand: Spectrum Pharmaceuticals. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Small molecule therapeutics for oncology and hematology are developed. | sppirx.com |
Business activity
The main business activity of Spectrum Oncology is professional, scientific and technical. In detail, this covers scientific research and development.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M5 | Scientific research and development |
To see the full business activity and turnover split of Spectrum Oncology Private Limited, buy the company report.
Financials of Spectrum Oncology Private Limited
FY 2023 filings availableSpectrum Oncology Private Limited reported revenue of ₹3.91 Cr (up 14% YoY) for FY 2023.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 1% over five years, including 14% growth in the latest year. EBITDA rose 1% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | ₹3.91 Cr | ||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹45.32 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹29.95 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 11.6% | ||||
| Net Profit Margin | 7.7% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Spectrum Oncology Private Limited, buy the company report.
Board of directors of Spectrum Oncology Private Limited
Spectrum Oncology has 4 current directors and 16 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Arun Shankar Nanivadekar | Director | 30 Jun 2009 | 17 Years 4 Months | As last reported |
| Hemanshu Lalitbhai Kapadia Also directs: Perfunova (International) Limited, Integrated Pesticides Private Limited, DNH and DD Power Corporation Limited and 1 more | Irp/Rp/Liquidator | 09 May 2024 | 2 Years 5 Months | As last reported |
| Purvish Mahendra Parikh Also directs: Medintel Services Private Limited | Director | 30 Jun 2009 | 17 Years 4 Months | As last reported |
| Satyanarain Rameshwardas Agarwala Also directs: Blue Cross Laboratories Private Limited | Director | 01 May 2008 | 18 Years 6 Months | As last reported |
Peer comparison
Spectrum Oncology Private Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Transcell Oncologics Private Limited | ₹4.04 Cr (FY 2023) | 3.0% | Hyderabad, Telangana, India | |||
| Sugen Life Sciences Private Limited | ₹4 Cr (FY 2025) | -11.0% | Tirupati, Andhra Pradesh, India | |||
| Spectrum Oncology Private Limitedthis company | ₹3.91 Cr (FY 2023) | ₹29.95 Lakh | 7.7% | 14.0% | Mumbai, Maharashtra, India | |
| Clinovi Research Private Limited | ₹3.85 Cr (FY 2024) | 2.0% | Pune, Maharashtra, India | |||
| Vignasai Laboratories Private Limited | ₹3.81 Cr (FY 2024) | 113.0% | Medchal Malkajgiri, Telangana, India | |||
| Biocad India Private Limited | ₹3.78 Cr (FY 2021) | -59.0% | Bangalore, Karnataka, India |
To see the full peer comparison of Spectrum Oncology Private Limited, buy the company report.
Auditor
Spectrum Oncology Private Limited is audited by GMJ & Co for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| GMJ & Co | FY 2023 | 103429W |
Shareholding
The shareholding of Spectrum Oncology Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Spectrum Oncology Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Spectrum Oncology Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Spectrum Oncology Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Spectrum Oncology has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AABCO0640G1ZT | Maharashtra | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Spectrum Oncology Private Limited, buy the company report.
Recent activity
Spectrum Oncology Private Limited has 20 board changes on record since 2008: 4 appointments and 16 cessations. The latest: Hemanshu Lalitbhai Kapadia was appointed as Irp/Rp/Liquidator on 09 May 2024.
11 earlier events are in the company report.
News
Frequently asked questions
Spectrum Oncology is currently "Under Liquidation" as per MCA records. The company's assets are being sold to settle outstanding debts owed to creditors. A company under liquidation may not have the legal capacity to fulfil new contracts, and creditors are prioritised in the distribution of proceeds. This is a high-risk status - caution is strongly advised.
Spectrum Oncology is a company under liquidation, formerly operating as a private limited company based in Mumbai, Maharashtra, India. The company works in pharma contract r and d, within the pharma industry. It was incorporated on 01 May 2008 and is registered under CIN U51397MH2008PTC181835. Caution is advised - the company may not have the legal capacity to fulfil new agreements.
Spectrum Oncology has 4 current directors:
- Arun Shankar Nanivadekar - Director
- Purvish Mahendra Parikh - Director
- Satyanarain Rameshwardas Agarwala - Director
- Hemanshu Lalitbhai Kapadia - Irp/Rp/Liquidator
The latest financial statements of Spectrum Oncology on record with the MCA are for the year ended 31 March 2023. Its last annual general meeting was held on 05 July 2023. Year-wise statements from 2015 are in the company report.
The CIN (Corporate Identification Number) of Spectrum Oncology is U51397MH2008PTC181835. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Spectrum Oncology was incorporated on 01 May 2008. It is registered with the Registrar of Companies, Mumbai.
The peers of Spectrum Oncology by revenue are Transcell Oncologics Private Limited, Sugen Life Sciences Private Limited, Clinovi Research Private Limited, Vignasai Laboratories Private Limited, Biocad India Private Limited, all in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development).
Hemanshu Lalitbhai Kapadia was appointed as Irp/Rp/Liquidator on 09 May 2024. Keith Matthew Mcgahan ceased to be Nominee Director on 12 Sep 2023. Joseph Wayne Turgeon ceased to be Director on 29 Mar 2022. Spectrum Oncology has 20 board changes on record in total.
Spectrum Oncology can be reached through the website sppirx.com. Its registered office is in Mumbai, Maharashtra, India.
The registered office of Spectrum Oncology is at Ofc No 1 Sadhana Bldg Gr Flr 207, David Barreto Rd Opp Wadala Stn Wadala West, Mumbai, Maharashtra, India – 400031.
The GSTIN of Spectrum Oncology is 27AABCO0640G1ZT, registered in Maharashtra.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
